We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Expanded Platelet Safety Measure Testing Officially Cleared

By LabMedica International staff writers
Posted on 15 Jun 2015
Print article
Image: The Platelet PGD Test is a rapid, qualitative immunoassay for the detection of aerobic and anaerobic Gram-positive and Gram-negative bacteria in platelets for transfusion (Photo courtesy of Verax Biomedical).
Image: The Platelet PGD Test is a rapid, qualitative immunoassay for the detection of aerobic and anaerobic Gram-positive and Gram-negative bacteria in platelets for transfusion (Photo courtesy of Verax Biomedical).
A rapid test for the detection of bacterial contamination in platelets intended for transfusion has received official clearance for use in hospitals or transfusion services.

The presence of bacteria in platelets can pose serious risks for patients, including sepsis, a life-threatening infection in the blood stream. The test is a more cost effective and less invasive approach to platelet bacterial safety than pathogen inactivation technologies.

Most health care facilities currently use single donor platelets (SDPs) or whole blood derived platelets (WBDs). As health care facilities expand their use of other platelet types, the official clearance means facilities will be able expand their use of the Platelet Pan Genera Detection (PGD) test to help reduce infectious risk to their patients.

The US Food and Drug Administration (Silver Springs, MD, USA) clearance of the Platelet PGD test (Verax Biomedical; Marlborough, MA, USA) means the test can now be used as a Safety Measure to check two additional platelet types: pre-storage pool platelets , for example Acrodose platelets (Pall Corporation; Port Washington, NY, USA), and apheresis platelets in platelet additive solution (PAS-C) and plasma.

The Verax Platelet PGD test is a single-use, lateral flow, qualitative test comprising reagents, controls, disposables and a test device containing two simultaneously run test strips specific for the detection of aerobic and anaerobic bacteria. The immunoassay is used on the day of transfusion at the point of care in the hospital or transfusion service to quickly detect bacterial contamination in platelets and protect patients from receiving contaminated transfusions. Annually, more than six million platelet doses are transfused worldwide, and approximately 1 in 2,000 doses are contaminated by bacteria.

Jim Lousararian, JD, CEO of Verax Biomedical, said, “Bacterial contamination of platelets is the number one infectious risk to transfusion recipients, and this FDA clearance makes the Verax Platelet PGD test the industry standard when it comes to the detection of bacteria in platelets. We applaud FDA for taking this critical step to help ensure patient safety and we look forward to continuing to work with the Agency, the transfusion community and other health care stakeholders to combat the severe risk of bacterial contamination in the US blood supply.”

Related Links:

US Food and Drug Administration 
Verax Biomedical
Pall Corporation 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.